The research suggests the nature and outcome of medulloblastoma relapse are biology and therapy dependent, providing translational opportunities for improved disease management through ongoing surveillance, prognostication, and risk-stratified selection of second-line treatments.
Using a combination of proteomic analyses and DNA and RNA sequencing to profile breast cancer tumors could lead to more effective, tailored treatment, suggests research from the Broad Institute and Baylor College of Medicine.
By expressing neuron-enriched mitochondrial proteins at an early stage of the direct reprogramming process, the researchers achieved a four times higher conversion rate and simultaneously increased the speed of reprogramming.
An artificial neural network can accurately predict the prognosis of melanoma patients based on pre-treatment histology images, shows research led by the NYU Grossman School of Medicine.
Researchers have developed an advanced technique, named VIRIM (virus infection real-time imaging), that makes it possible for the entire course of a virus infection to be visualized in the lab with great precision.
The researchers discovered several drugs stopped growth of cells from the most aggressive medulloblastoma subtype: actinomycin D, oleandrin, gambogic acid, idarubicin, and bortezomib. In a study of live mice with the patient-derived xenograft cells, actinomycin D extended their survival.
The researchers examined correlations between levels of the neurofilament light protein and the degree of brain injury, in addition to neurological, functional, or cognitive status of patients at the time their blood was collected.
An altered transgene lowered transgene expression in the dorsal root ganglia by more than 80% and reduced toxicity in primates—considered a major hurdle to gene therapy for central nervous system conditions.
The gene CRELD1, known to play an important role in the development of the heart in the embryo, has now been shown to be an important gatekeeper of immune system homeostasis, according to researchers at the University of Bonn in Germany.
In cell culture experiments, sera from both older and younger uninfected individuals with cross-reactive antibodies showed the ability to neutralize SARS-CoV-2 and SARS-CoV-2 S pseudotypes, whereas sera from uninfected patients lacking cross-reactive antibodies exhibited no such neutralizing activity.